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Abstract
Background: The outcomes of treatment of ruptured varices in patients with hepatocellular carcinoma (HCC) and
portal vein tumor thrombus (PVTT) are unclear. We therefore evaluated the long- (rebleeding and death) and short-
term (immediate death within 24 h of variceal bleeding diagnosis) outcomes of patients with PVTT who underwent
emergency variceal band ligation.
Methods: Data on 62 patients with PVTT and endoscopically proven esophageal or gastric variceal bleeding from
2007 to 2012 were studied. In most cases, the varices were treated using endoscopic variceal band ligation (EVL).
We assessed the patients’ rebleeding-free and overall survival using the Kaplan-Meier method, and a Cox proportional
hazard model was used to analyze effect of independent factors on rebleeding-free and overall survival times.
Results: Most patients had decompensated cirrhosis and were classified as Child-Pugh class B (56 %) or C (36 %). A
total of 35 patients (56 %) had PVTT in the main portal trunk. Among all patients, 58 (94 %) and 4 (6 %) had esophageal
and gastric variceal bleeding, respectively. Bleeding was managed using EVL in all, but one patient (98 %) who was
treated with a Sengstaken-Blakemore tube. A total of 24 patients (39.3 %) experienced rebleeding, and these patients
had a median overall survival time of 36 days. A PVTT in the main portal trunk was predictive of rebleeding (hazard
ratio 3.706, p = .0223), and α-fetoprotein-L3 levels <37.4 % (hazard ratio 0.464, p = 0.015) and Child-Pugh class A/B
(hazard ratio 0.398, p = 0.007) were associated with overall survival. We observed 95 bleeding events in 62 patients. EVL
achieved hemostasis in 92 of the 95 bleeding events, whereas seven immediate deaths occurred due to variceal
bleeding (7/92, 7.6 %). All three bleeding events treated with modalities other than EVL resulted in immediate deaths.
Conclusions: EVL is a safe and effective treatment of variceal ruptures in patients with HCC and PVTT. After successful
hemostasis, alleviation of the underlying liver function impairment and tumor control are equally important for a good
prognosis.
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Background
Hepatocellular carcinoma (HCC) is the sixth most com-
mon cancer worldwide [1]. Due to the condition’s very
poor prognosis, the number of deaths due to HCC is
similar to its incidence, making it the third most com-
mon cause of cancer-related deaths [1]. The majority of
HCC cases develop as part of the natural course of liver
cirrhosis [2]. Despite the recommended surveillance,
HCC is often only detected at an advanced stage [3, 4],
particularly in patients with a portal vein tumor
thrombus (PVTT; 12.5–39.7 % of cases) [4–8]. Although
an increasing variety of therapeutic options that offer
survival benefits are available for patients with HCC [9],
the long-term prognosis of HCC remains poor because
HCC recurrence and PVTT development remain un-
controllable [10].
A PVTT significantly affects the prognosis of HCC pa-
tients because it often leads to the extensive spread of
the tumor throughout the liver and increases portal
blood pressure, resulting in variceal ruptures, ascites,
hepatic encephalopathy, liver failure, and death [11].
There has been a substantial improvement in the sur-
vival of patients with variceal bleeding owing to the use
of vasoactive drugs [12], the introduction of endoscopic
variceal band ligation (EVL) [13–15] and endoscopic in-
jection sclerotherapy (EIS) [16, 17]. Several studies have
examined the prognoses associated with variceal bleed-
ing, but most have been observational studies that have
excluded patients with HCC [18–23]. Therefore, the
long-term outcomes of ruptured variceal treatment in
patients with advanced HCC and PVTT remain unclear.
This study evaluated the long- (rebleeding and death)
and short-term (immediate death) outcomes of HCC
patients with ruptured esophageal or gastric varices and
a PVTT.
Methods
Study design, setting, and data collection
We conducted a retrospective study using data from a
database that included all patients admitted to the
Kyoundo Hospital (Tokyo, Japan) for HCC between
January 2007 and December 2012. The database was
part of a project to evaluate the effect of current therap-
ies on the prognosis of PVTT-related variceal bleeding
and was approved by the Institutional Review Board of
the Kyoundo Hospital. All data were collected in the
context of standard practice from patient clinical re-
cords, anonymized, and populated into a protected
database.
Diagnosis of hepatocellular carcinoma, portal vein tumor
thrombi, and variceal bleeding
HCC was diagnosed based on standard computed tom-
ography (CT) findings [24]. A PVTT was defined as the
presence of HCC invading the main trunk or the first or
second branches of the portal vein on CT findings. Gas-
tric varices were classified based on the following criteria
[25]: Gastroesophageal varices (GOVs) were associated
with varices along the lesser curvature of the stomach
(type 1 [GOV1]) or along the fundus (type 2 [GOV2]).
Isolated gastric varices (IGVs) were present in isolation
in the fundus, at ectopic sites in the stomach (IGV1), or
at the first part of the duodenum (IGV2). The status of
each patient was assessed at the time of admission.
All patients were diagnosed as having bleeding esopha-
geal or gastric varices by emergency endoscopy within
24 h of the hemorrhage. Acute variceal bleeding was di-
agnosed when blood was observed to emanate from a
varix, or when fresh blood was seen in the esophagus of
patients with varices displaying the white nipple sign
[26] and in whom no other potential site of bleeding
was identified. Standard therapy for variceal bleeding in-
cluded blood transfusions, fluid and electrolyte replace-
ment, and lactulose administration, as necessary.
Endoscopic variceal band ligation
Following the emergency endoscopy to identify the
bleeding points, a flexible overtube (Sumitomo Bakelite,
Tokyo, Japan) was inserted, and the esophageal varices
were ligated using a pneumatic EVL device (Sumitomo
Bakelite). Ligation was initially applied at the bleeding
point and performed with 1–3 rubber bands. After the
ligation was completed, the ligation sites were sprayed
with water and suctioned to check for persisting bleed-
ing. Rescue therapies (e.g., a Sengstaken-Blakemore bal-
loon tamponade [27]) were applied when necessary.
Initial success was defined as bleeding cessation and vital
sign stabilization.
Follow-up of patients
Follow-up of the enrolled patients was continued until
December 2013. Data regarding patient demographics,
liver disease, and bleeding episodes were registered in
the database.
Variables and statistical analysis
Recurrent bleeding was defined as hematemesis recur-
ring after initial EVL treatment. Immediate death was
defined as death within 24 h of diagnosing the variceal
bleeding. Rebleeding-free survival was calculated from
the initial date of the therapy to the date of rebleeding
or death and assessed by the Kaplan-Meier method.
Overall survival was defined as the interval from the ini-
tial treatment to death. A Cox proportional hazard
model was used to analyze the effects of independent
factors on survival. Possible predictors entered into the
model included patient characteristics (age and sex),
viral characteristics (hepatitis B virus surface antigen and
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hepatitis C virus antibody levels), the presence of ascites,
the presence of encephalopathy, tumor characteristics
(maximum tumor dimension, tumor number, portal vein
invasion, and extrahepatic metastasis), laboratory test re-
sults (albumin, alanine transaminase, aspartate trans-
aminase, and total bilirubin levels; prothrombin time;
and platelet count), and serum levels of tumor markers
(α-fetoprotein [AFP], AFP-L3, and des-gamma carboxy-
prothrombin [DCP]), site of variceal rupture, EVL suc-
cess, and the presence of rebleeding varices. Each
continuous variable was transformed into categorical data
consisting of two ordinal numbers using the median value
for Cox regression analyses, except for AFP and DCP. The
cutoff values were set at 100 ng/mL and 100 mAU/mL for
AFP and DCP, respectively [10]. All statistical analyses
were considered significant at p < 0.05. Statistical analysis
was performed with the Stat View 5.0 statistical software
(SAS Institute, Cary, NC, USA).
Results
Patient characteristics
A total of 2123 HCC patients who were admitted to the
Kyoundo Hospital between January 2007 and December
2012 were retrospectively registered in the database.
Among these, 472 patients (22.2 %) had a PVTT and 62
(62/472; 13.1 %) were diagnosed with bleeding varices.
Thus, the final analysis included 62 patients (Fig. 1).
The median age of the patients was 62 years (range,
30–79 years), 51 (82 %) were men and 11 (18 %) women
(Table 1). The patients’ liver cirrhosis etiologies were
hepatitis B (n = 25; 40 %), hepatitis C (n = 27; 44 %), and
non-B non-C hepatitis (n = 10; 16 %). The patients were
classified based on their liver function as Child-Pugh
classes A (n = 5; 8 %), B (n = 35; 56 %), or C (n = 22;
36 %). Among all patients, 56 % had a PVTT in the main
portal trunk, and 27 % had extrahepatic metastasis.
None of the patients had a history of preventive proce-
dures for varices.
Variceal bleeding and occurrence of rebleeding
Upper gastrointestinal tract endoscopic examination for
the bleeding sites revealed that 58 (94 %) and 4 (6 %) pa-
tients had esophageal and gastric variceal bleeding, re-
spectively. All were classified as GOV1. The bleeding
was managed using EVL except for one patient who was
treated with a Sengstaken-Blakemore tube. Complete
initial hemostasis was achieved in all patients.
A total of 24 patients (39.3 %) experienced rebleeding.
Although EVL successfully stopped the initial bleeding,
33 rebleeding events occurred in 62 patients (0–5 rebleed-
ing events in each patient). A total of 4 and 14 patients ex-
perienced rebleeding within 7 and 30 days, respectively
(Table 2).
Rebleeding-free and overall survival
The median rebleeding-free survival time was 29 days
(95 % CI, 18–40 days), and the 7-, 30-, 60-day, and 1-
Fig. 1 Flowchart of the study cohort selection. A total of 2123 hepatocellular carcinoma patients who were admitted to the Kyoundo Hospital
between January 2007 and December 2012 were retrospectively registered in the database. Among these, 472 patients (22.2 %) had a portal vein
tumor thrombus, and 62 (62/472; 13.1 %) experienced bleeding varices. HCC hepatocellular carcinoma, PVTT portal vein tumor thrombus
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year rebleeding-free survival rates were 79.0, 50.0, 30.6,
and 6.5 %, respectively (Fig. 2).
We detected a median overall survival time of 36 days
(95 % CI, 23–63 days; Fig. 4). The 7-, 30-, 60-day, and 1-
year overall survival rates were 83.9, 59.7, 38.7, and
8.1 %, respectively (Fig. 3). Despite achieving initial
hemostasis, 10 patients died within 1 week. Only one pa-
tient survived for more than 5 years in this study. This
patient developed HCC following hepatitis B-related cir-
rhosis in 2003. In 2007, a PVTT was found in the left
branch of the patient’s portal vein, and arterial infusion
chemotherapy with 5-fluorouracil in combination with
interferon was administered [28]. An esophageal varix
rupture occurred during chemotherapy, and EVL was
performed. After hemostasis, arterial infusion chemo-
therapy was continued, resulting in tumor shrinkage and
PVTT disappearance. The patient did not experience
any rebleeding and was still alive in 2015.
Prognostic factors for rebleeding-free survival
Among the 21 possible predictors we examined, our uni-
variate analysis showed that a PVTT in the main trunk
was the only significant factor affecting rebleeding-free
survival (hazard ratio 3.706, p = 0.0223; Table 3). The
median rebleeding-free survival time was 24 days in the
patient group with a PVTT in the main portal trunk and
34 days in the patient group with a PVTT in the first or
second branches of the portal vein (p = 0.6313).
Prognostic factors for overall survival
Sixteen in-hospital deaths occurred among the patients
included in this study. Overall survival was affected by
Child-Pugh class (p < 0.0001), AFP-L3 levels (p = 0.0080),
and prothrombin time (p = 0.0161) in the univariate ana-
lysis (Table 4). The multivariate analysis showed that
Child-Pugh class A/B (hazard ratio 0.398, p = 0.0065)
and AFP-L3 levels <37.4 % (hazard ratio 0.464, p =
0.0147) were independent prognostic factors of overall
survival (Table 5). The median overall survival time was
18 days for Child-Pugh class C patients and 64 days for
Child-Pugh class A/B patients (p < 0.0001, Fig. 4).
Immediate death rates
We observed 95 bleeding events in 62 patients (1–6
events in each patient). EVL achieved hemostasis in 92
of the 95 bleeding events, and seven immediate deaths
due to variceal bleeding (7/92; 7.6 %) were recorded. Of
the three bleeding events treated with modalities other
than EVL, all resulted in immediate deaths, indicating
that EVL is useful for preventing immediate deaths after
variceal bleeding (p = 0.0009).
Discussion
Up to 40 % of patients with acute bleeding from esopha-
geal varices have been reported to die from exsanguin-
ation; in other cases, death is due to bleeding
complications, including liver failure, infections, and
hepatorenal syndrome [29, 30]. Our study shows that
EVL can produce a high rate of successful hemostasis in
patients with variceal ruptures and a PVTT. EVL-treated
bleeding events resulted in significantly lower immediate
mortality rates than those treated with other modalities,
suggesting that EVL is useful for preventing immediate
death due to exsanguinating variceal bleeding.
Table 1 Patient baseline characteristics
Variable
Age (years) 62 (30–79)
Sex (male/female) 51/11
Viral infection (HBV/HCV/NBNC) 25/27/10
Ascites (+/−) 12/50
Encephalopathy (+/−) 8/54
Albumin (g/dL) 2.9 (1.7–4.1)
Total bilirubin (mg/dL) 1.4 (0.4–21.4)
Prothrombin time (%) 68 (15–120)
Platelet count (× 104/mm3) 12.0 (2.6–67.2)
AST (IU/L) 117.0 (26–2882)
ALT (IU/L) 48.5 (11–865)
Child-Pugh class (A/B/C) 5/35/22
Tumor size (cm) 6.8 (1.6–20)
Tumor number (single/multiple) 5/57
Extrahepatic metastasis (+/−) 17/45
PVTT (main trunk/others) 35/27
AFP (ng/dL) 1780.5 (2–3535473)
AFP-L3 (%) 37.4 (0.5–94.2)
DCP (ng/dL) 7260 (7–402000)
Variceal rupture (esophagus/stomach) 58/4
AFP α-fetoprotein, AFP-L3 lectin-reactive α-fetoprotein, ALT aspartate
aminotransferase, AST alanine aminotransferase, DCP des-gamma
carboxyprothrombin, HBV hepatitis B virus, HCV hepatitis C virus, NBNC
non-B non-C hepatitis, PVTT portal vein tumor thrombus
Table 2 Outcomes of endoscopic variceal band ligation
Hemostasis rate 98.4 %
(61/62)
An SB tube was used
in one patient
Rebleeding rate 39.3 %
(24/61)











MST median survival time, SB Sengstaken-Blakemore
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Fig. 2 Rebleeding-free survival. The 7-, 30-, 60-day, and 1 year rebleeding-free survival rates were 79.0, 50.0, 30.6, and 6.5 %, respectively
Fig. 3 Overall survival. The 7-, 30-, 60-day, and 1-year overall survival rates were 83.9, 59.7, 38.7, and 8.1 %, respectively
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Other than EVL, treatments for variceal bleeding in-
clude medical treatment with vasoactive drugs, balloon
tamponade, placement of fully covered self-expanding
metallic stents [31], transjugular intrahepatic portosyste-
mic shunts [32], and surgical shunts [33]. Self-expanding
metallic stents are not considered effective for the treat-
ment of variceal bleeding due to their high associated in-
cidence of rebleeding [34]. Transjugular intrahepatic
portosystemic shunts and surgical shunts are also not in-
dicated in patients with a PVTT and/or poor liver func-
tion. Some studies have reported endoscopic treatment
of varices in patients with portal HCC invasion. Ng et al.
reported data on 14 patients with bleeding esophageal
varices and HCC, including 12 who had a PVTT. Suc-
cessful bleeding control by emergency EIS was achieved
for only 6 of 22 bleeding episodes (27 %) [35]. Naka-
shima et al. reported that in 6 patients with bleeding
esophageal varices and HCC portal invasion, the initial
variceal hemorrhage was successfully controlled follow-
ing EIS (100 %). However, 4 of the 6 patients (66.7 %)
experienced rebleeding and died of a hemorrhage and
liver failure within 1 month [36]. In a study by Ohta et
al., acute variceal bleeding was controlled following
emergency EIS in 28 of 29 PVTT patients with bleeding
esophageal varices (96.6 %) [37]. Our study showed a
hemostasis rate of 98.3 %. Thus, based on these earlier
reports, EVL was as effective as EIS. Moreover, EVL is
now widely available, complications are less common
than for EIS [18], and the associated mortality rates are
lower than for sclerotherapy [14, 15]. Our findings con-
firm that EVL is effective for hemostasis and prevention
of immediate death in patients with HCC and a PVTT.
In the present study, we did observe a high rate of
rebleeding (39.3 %). A PVTT in the main trunk was
Table 3 Significant predictors for rebleeding-free survival
Variable Hazard ratio 95 % CI p value
Age >62 years 0.466 0.165–1.318 0.1500
Sex (male) 1.129 0.292–4.360 0.8602
HCV 1.046 0.338–3.238 0.9382
NBNC 1.778 0.403–7.845 0.4474
Ascites (+) 1.333 0.354–5.026 0.6709
Encephalopathy (+) 1.780 0.382–7.559 0.4857
Albumin >2.9 g/dL 0.714 0.255–2.003 0.5224
Total bilirubin >1.4 mg/dL 0.436 0.153–1.244 0.1208
Prothrombin time >68 % 1.729 0.615–4.860 0.2987
Platelet count >12.0 × 104/mm3 2.147 0.759–6.074 0.1500
AST >117 IU/L 0.643 0.229–1.804 0.4012
ALT >48.5 IU/L 1.729 0.615–4.860 0.2987
Child-Pugh class C 0.458 0.149–1.414 0.1746
Tumor size (>6.8 cm) 1.438 0.86–2.403 0.166
Tumor number (single) 0.287 0.031–2.662 0.2687
Extrahepatic metastasis (+) 1.153 0.369–3.600 0.8064
PVTT (main trunk) 3.706 1.205–11.401 0.0223
AFP >100 ng/dL 0.714 0.234–2.177 0.5540
AFP-L3 > 37.4 % 1.385 0.439–4.372 0.5790
DCP >100 ng/dL 3.485 0.381–31.839 0.2687
Variceal rupture (stomach) 5.286 0.516–54.103 0.1606
AFP alpha-fetoprotein, AFP-L3 lectin-reactive alpha-fetoprotein, ALT aspartate
aminotransferase, AST alanine aminotransferase, CI confidence interval, DCP
des-gamma carboxyprothrombin, HCV hepatitis C virus, NBNC non-B non-C
hepatitis, PVTT portal vein tumor thrombus
Table 4 Independent prognostic factors for overall survival
(univariate analysis)
Variable Hazard ratio 95 % CI p value
Age <62 years 0.752 0.448–1.263 0.2813
Sex (female) 0.794 0.412–1.529 0.4895
HBV 0.859 0.402–1.836 0.6956
HCV 1.509 0.727–3.131 0.2698
Ascites (−) 0.923 0.408–1.747 0.8058
Encephalopathy (−) 0.532 0.289–1.135 0.1425
Albumin <2.9 g/dL 1.084 0.651–1.805 0.7565
Total bilirubin <1.4 mg/dL 0.601 0.359–1.007 0.0533
Prothrombin time <68 % 1.882 1.125–3.150 0.0161
Platelet count <12.0 × 104/mm3 0.692 0.413–1.158 0.1618
AST <117 IU/L 0.631 0.374–1.063 0.0834
ALT <48.5 IU/L 0.744 0.442–1.253 0.2664
Child-Pugh class A/B 0.350 0.179–0.554 <0.0001
Tumor size (<6.8 cm) 0.696 0.416–1.163 0.1540
Tumor number (multiple) 2.296 0.903–5.842 0.0810
Extrahepatic metastasis (−) 0.800 0.455–1.407 0.4385
PVTT (without main trunk) 1.284 0.762–2.162 0.3467
AFP <100 ng/dL 0.619 0.352–1.088 0.0958
AFP-L3 < 37.4 % 0.452 0.252–0.813 0.0080
DCP <100 ng/dL 0.481 0.189–1.220 0.1233
Variceal rupture (esophagus) 1.209 0.435–3.344 0.7193
EVL (−) 2.031 0.279–14.802 0.4844
Rebleeding (−) 1.091 0.651–1.826 0.7415
AFP α-fetoprotein, AFP-L3 lectin-reactive α-fetoprotein, ALT aspartate
aminotransferase, AST alanine aminotransferase, CI confidence interval, DCP
des-gamma carboxyprothrombin, EVL endoscopic variceal band ligation, HBV
hepatitis B virus, HCV hepatitis C virus, PVTT portal vein tumor thrombus
Table 5 Independent prognostic factors for overall survival
(multivariate analysis)
Variable Hazard ratio 95 % CI p value
Prothrombin time <68 % 1.383 0.742–2.575 0.3071
Child-Pugh class A/B 0.398 0.205–0.773 0.0065
AFP-L3 < 37.4 % 0.464 0.251–0.860 0.0147
AFP-L3 lectin-reactive α-fetoprotein, CI confidence interval
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predictive for rebleeding. In HCC patients with a PVTT
in the main trunk, varices are exacerbated due to the
marked elevation of portal vein pressure, leading to
rebleeding despite initial hemostasis. The treatment of
rebleeding is often difficult in these patients, and sec-
ondary prevention of variceal rupture is important for
improving the patients’ prognoses.
We only studied the emergency treatment of variceal
ruptures and therefore cannot discuss the advantages of
preventive therapy for varices after initial hemostasis.
However, variceal and concurrent HCC treatment might
decrease bleeding frequency and improve patient prog-
nosis. For example, Wu et al. reported that sorafenib, an
oral multikinase inhibitor, could improve the outcome of
variceal bleeding in patients with portal trunk or main
branch HCC invasion [38]. In addition, Katamura et al.
showed that intra-arterial 5-fluorouracil/interferon-α
combined with three-dimensional conformal radiation
therapy for a PVTT improved the PVTT response rate
and reduced the incidence of portal hypertension-related
events [39]. The median survival time of the patients
classified as Child-Pugh class A was 133 days in this
study, which might be long enough to effectively shrink
a PVTT using chemotherapy with sorafenib, 5-
fluorouracil hepatic arterial infusion with systemic inter-
feron, or radiation to reduce portal vein pressure and
the risk of rebleeding. Therefore, we speculate that des-
pite being limited to patients in good general condition
having good hepatic function, treatment for PVTT, lead-
ing to decreased portal vein pressure, might prevent
rebleeding. In this study, one patient survived for more
than 5 years. If endoscopic hemostasis is successful and
liver cancer is controlled, as in this patient, prolonged
survival of similar patients might be achievable.
After initial hemostasis success using EVL, rebleeding-
free survival was predicted by the presence of a PVTT
in the main trunk influencing portal vein pressure, and
overall survival was predicted by Child-Pugh class and
AFP-L3 levels, which are not directly related to variceal
severity, but rather reflect liver function and the malig-
nant potential of the HCC a determinant of prognosis.
Thus, EVL treatment of bleeding varices appears to be
sufficiently effective in ensuring that patient survival is
no longer affected by bleeding varices but by overall liver
function and tumor progression. For better survival of
HCC patients with a PVTT concurrent with varices,
control of HCC/PVTT and preservation or restoration
of liver function are as important as variceal treatment.
Although our study showed that the prognosis of HCC
patients with a PVTT and bleeding varices was still poor,
preventative therapy for varices might prevent variceal
ruptures. Since this study was a retrospective study
Fig. 4 Overall survival based on Child-Pugh classification. The solid line connecting the “×” symbols indicates the overall survival of patients
classified as Child-Pugh class C, whereas the dotted line connecting the “+” symbols indicates the overall survival of patients classified as
Child-Pugh class A/B (p < .0001)
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dealing with only emergency hemostasis, the significance
of prophylactic variceal treatment in HCC patients with
a PVTT could not be assessed. A future prospective
study on preventive variceal therapy in these patients is
required.
Conclusions
We evaluated the long- and short-term outcomes of pa-
tients with a PVTT who experienced potentially fatal
ruptures of their esophageal or gastric varices. We found
a rebleeding rate of 39.3 % and a median overall survival
time of 36 days. A PVTT in the main portal trunk was
predictive of rebleeding, and AFP-L3 levels and Child-
Pugh class were predictive of overall survival. All EVL-
treated patients in this study achieved initial complete
hemostasis. Therefore, EVL of variceal ruptures in pa-
tients with a PVTT can achieve hemostasis and is useful
for preventing immediate death from variceal bleeding.
We conclude that EVL is a safe and effective treatment
of variceal ruptures in patients with HCC and PVTT.
After successful hemostasis, the alleviation of the under-
lying liver function impairment and tumor control are
equally important for a good prognosis.
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